Concord Medical Services Holdings (CCM) EBITDA (2009 - 2025)

Concord Medical Services Holdings has reported EBITDA for 17 years, with the latest figure at -$27.7 million in Q2 2025.

• For the quarter ending Q2 2025, EBITDA rose 39.91% year-over-year to -$27.7 million; the trailing twelve-month figure through Jun 2025 stood at -$150.6 million (down 1.4% YoY), and the FY2025 full-year result was -$54.0 million, down 23.12% from the prior year.
• EBITDA for Q2 2025 stood at -$27.7 million, up from -$46.1 million in the prior quarter.
• The five-year high for EBITDA was -$25.6 million in Q2 2021, with the low at -$46.1 million in Q2 2024.
• Historically, EBITDA has averaged -$35.2 million across 5 years, with a median of -$31.4 million in 2023.
• Annual changes were most pronounced in 2022 — EBITDA slumped 77.17% — and 2025, when it surged 39.91%.
• Concord Medical Services Holdings' EBITDA stood at -$25.6 million in 2021, then slumped by 77.17% to -$45.4 million in 2022, then jumped by 30.83% to -$31.4 million in 2023, then tumbled by 46.79% to -$46.1 million in 2024, then surged by 39.91% to -$27.7 million in 2025.
• The last three EBITDA figures came in at -$27.7 million (Q2 2025), -$46.1 million (Q2 2024), and -$31.4 million (Q2 2023), per Business Quant data.